Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

What's Next for the Treatment of ccRCC? HIF-2α Inhibitors: Angiogenesis, Tumorigenesis, and Emerging Agents

Premiere Date: Tuesday, November 30, 2021

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, November 30, 2022
Note: Credit Is No Longer Available

Faculty

Xin Gao, MD (Moderator) Assistant Professor of Medicine, Harvard Medical School Genitourinary Cancers Program Developmental Therapeutics/Phase 1 Investigational Program Massachusetts General Hospital Cancer Center Boston, MA

Eric Jonasch, MD  Professor of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX

Statement of Need

Loss of von Hippel-Lindau (VHL) protein in patients with VHL disease leads to HIF-2α-driven hemangioblastomas and kidney, pancreatic, and other types of tumors. VHL protein is also defective or absent in the majority of sporadic clear cell renal cell carcinomas (ccRCCs). Early data suggests HIF-2α inhibitors may provide clinical benefit in the management of ccRCC. Given the novelty of HIF-2α inhibitors, clinicians have no experience with these agents, and need education on HIF-2α regulation of angiogenesis, tumorigenesis, and emerging agents targeting this protein complex.

This CMEOCast podcast focuses on the function of critical components of the VHL-HIF2α-VEGF axis and the potential value of HIF-2α inhibitors in the treatment of VHL disease-associated tumors and ccRCC.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Recognize the function of critical components of the VHL-HIF2a-VEGF axis regulating angiogenesis in cancer.
• Identify the potential value of HIF-2a inhibitors in the treatment of ccRCC.

Financial Support

Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Target Audience

Oncologists, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gao reports the following financial relationships:

Consultant: Bayer; Dendreon Pharmaceuticals LLC; Exelixis, Inc.; Flare Therapeutics Inc.; and Guardant Health

Research Support:(Principal Investigator & Institution Paid) Aravive; Arvinas; Exelixis, Inc.; Harpoon Therapeutics; Merck & Co., Inc.; Pfizer Inc.; Poseida Therapeutics, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and TopAlliance Biosciences

Dr. Jonasch reports the following financial relationships:

Consultant: Aravive; AVEO Pharmaceuticals, Inc.; Calithera Biosciences, Inc.; Eisai Inc.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; NiKang Therapeutics, Inc.; Novartis; and Pfizer, Inc.

Research Support: Merck & Co., Inc.; NiKang Therapeutics, Inc.; and Novartis

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

David Modrak, PharmD (planning committee) has no disclosures to report.

Julie Strickland, PharmD (planning committee) has no disclosures to report.

Kathleen Blake, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).